View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 7, 2020updated 12 Jul 2022 11:56am

Inovio commences Phase I trial of DNA vaccine for Covid-19

Inovio Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application of its DNA vaccine candidate INO-4800 against Covid-19.

Inovio Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application of its DNA vaccine candidate INO-4800 against Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Following the approval, the company has commenced a Phase I clinical trial of the vaccine candidate in healthy participants.

Inovio leveraged its DNA medicines platform to create the Covid-19 vaccine candidate. The company’s DNA medicines are designed to directly deliver optimised plasmids into cells intramuscularly or intradermally using its hand-held smart device Cellectra.

The Phase I trial will assess INO-4800 in up to 40 healthy adults at the University of Pennsylvania’s Perelman School of Medicine and at the Center for Pharmaceutical Research in the US. Screening of participants has been commenced at these sites.

Participants will be administered with two doses of INO-4800 four weeks apart. Initial immune responses and safety data are expected to be available in the coming months.

The vaccine candidate was subjected to preclinical testing in animal models, where it demonstrated encouraging immune response data, said the company.

Further preclinical trials, including challenge studies, will be conducted along with the Phase I trial.

Inovio Pharmaceuticals president and CEO Dr Joseph Kim said: “Without a new safe and effective vaccine, the Covid-19 pandemic is likely to continue to threaten lives and livelihoods. It also demonstrates the power of our DNA medicines platform to rapidly develop and advance a vaccine for Covid-19 into Phase I clinical testing.

“Our dedicated team of staff, partners and funders have been mobilised since the genetic sequence of the virus became available in early January and continues to work around the clock to ensure that we are rapidly advancing INO-4800 through this Phase I study towards planned efficacy trials.”

After obtaining Phase I preliminary safety and immunogenicity results, the company intends to launch Phase II efficacy studies of the Covid-19 vaccine candidate.

The company has already produced thousands of INO-4800 doses for Phase I and II trials. The aim is to generate one million doses by year-end for more trials and emergency use.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena